

*The American Journal of Psychiatry* requires its editors to disclose any financial relationships with commercial interests, including consulting with pharmaceutical companies or receiving honoraria from them. These relationships were as follows:

- Robert Freedman, M.D., holds a patent through the VA for discovery of a genetic variant in schizophrenia. He serves as an unpaid co-investigator at the University of Colorado and Denver VAMC for investigations sponsored by pharmaceutical companies that are developing new drugs for patients based on his research findings.

- David A. Lewis, M.D., received investigator-initiated research support from the BMS Foundation, Bristol-Myers Squibb, Curridium Ltd., Merck, and Pfizer. He has served as a consultant in the areas of target identification and validation and new compound development to AstraZeneca, BioLine RX, Bristol-Myers Squibb, Hoffman-Roche, Lilly, Merck, Neurogen, and SK Life Science.

- Robert Michels, M.D., reports no financial relationships with commercial interests.

- Daniel S. Pine, M.D., reports no financial relationships with commercial interests.

- Susan K. Schultz, M.D., reports no financial relationships with commercial interests.

- Carol A. Tamminga, M.D., has served on advisory boards for Acadia Pharmaceuticals and Intracellular Therapies; has received funding from Synosia; and has served as a consultant for Alexza Pharmaceuticals and Orexigen, a consultant and speaker for Lundbeck, Inc., and an expert witness for Finnegan Henderson Farabow Garrett & Dunner, LLP.